Stroke accounted for a 15.1% share of the global clinical trials within the Cardiovascular therapy area in 2021, registering an increase of 5.2% when compared with the last ten-year average of 9.9% share, according to GlobalData .

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Stroke

Industry sponsored trials held a 44.4% share of all the clinical trials for Stroke indication in 2021, registering an increase of 9.8% when compared with the ten-year average of 34.6%. Non-industry sponsored trials accounted for a 55.6% share in 2021, marking a decrease of 9.8% over the ten-year average of 65.4%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Stroke trials

Asia-Pacific was the top region for industry sponsored Stroke trials, accounting for a 58.3% share in 2021, when compared with the five-year average of 64.1% and ten-year average of 52.3%.

Europe was at the second position with a 33.1% share in 2021, over the five-year average of 32.0% and ten-year average of 43.5%, followed by Middle East and Africa with an 8.6% share in 2021, as against five-year and ten-year averages of 5.0% and 9.1% respectively.

North America stood fourth with an 8.6% share in 2021, compared with the five-year average of 19.2% and ten-year average of 23.6%, followed by South and Central America with a 1.4% share in 2021, over five-year and ten-year averages of 4.2% and 6.2% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Stroke trials, accounting for a 40.3% share in 2021, as against the five-year average of 33.7% and ten-year average of 23.5%.

Russia held a 27.3% share in 2021, over the five-year average of 17.3% and ten-year average of 24.3%, followed by Thailand with a 13.7% share in 2021, compared with the five-year and ten-year averages of 5.1% and 5.7% respectively.

The US held an 8.6% share in 2021, as against the five-year average of 17.1% and ten-year average of 21.4%.

Iran held a 6.5% share in 2021, over the five-year and ten-year averages of 0.4% and 0.4% respectively.

Top regions of non-industry sponsored Stroke trials

Asia-Pacific was the top region for non-industry sponsored Stroke trials, accounting for a 68.9% share in 2021 when compared with the five-year average of 58.2% and ten-year average of 55.5%.

Europe was at the second position with a 13.2% share in 2021, over the five-year and ten-year averages of 18.3% and 21.1% respectively, followed by Middle East and Africa with a 10.8% share in 2021, as against the five-year average of 13.3% and ten-year average of 10.7%.

North America stood at the fourth position with a 7.8% share in 2021, compared with the five-year average of 15.0% and ten-year average of 16.9%, followed by South and Central America with a 2.4% share in 2021, over the five-year and ten-year averages of 1.6% and 2.3% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Stroke trials, accounting for a 53.3% share in 2021, as against the five-year average of 40.1% and ten-year average of 32.5%.

Iran held an 8.4% share in 2021, over the five-year average of 9.4% and ten-year average of 7.8%, followed by US with a 6.6% share, compared with the five-year and ten-year averages of 11.3% and 12.5% respectively.

Australia held a 4.8% share in 2021, as against the five-year average of 4.4% and ten-year average of 4.2%.

South Korea held a 3.0% share in 2021, over the five-year average of 3.7% and ten-year average of 4.1%.

Phase I trials lead industry sponsored clinical trials for Stroke in 2021

Phase I trials held a 76.1% share of industry sponsored clinical trials for Stroke in 2021, over the five-year average of 52.7% and ten-year average of 44.7%.

Phase II trials held a 12.7% share in 2021, as against the five-year average of 20.7% and ten-year average of 18.6%. Phase III trials held a 9.2% share in 2021, compared with the five-year and ten-year averages of 13.4% and 19.1% respectively.

Phase IV trials held a 2.1% share in 2021, over the five-year average of 13.2% and ten-year average of 17.6%.

Phase II trials lead non-industry sponsored clinical trials for Stroke in 2021

Phase II trials held a 36.5% share of non-industry sponsored clinical trials for Stroke in 2021, over the five-year average of 40.2% and ten-year average of 40.0%.

Phase IV trials held a 28.7% share in 2021, as against the five-year average of 30.0% and ten-year average of 30.2%. Phase III trials held a 19.7% share, compared with the five-year and ten-year averages of 18.7% and 19.6% respectively.

Phase I trials held a 15.2% share in 2021, over the five-year average of 11.1% and ten-year average of 10.2%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.